Please login to the form below

Not currently logged in
Email:
Password:

GSK Biologicals signs Alzheimer's deal with AFFiRiS

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates.

The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. This allows the development of proteins that bind to the disease-causing human proteins that are central to the pathology of Alzheimer's disease.

Jean Stephenne, president and general manager of GlaxoSmithKline Biologicals said: "We are impressed with the AFFiRiS technology - combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease."

The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty payments. In the event of the vaccines reaching full commercial success and gaining government authority approval, the value of the agreement could reach £334m.

23rd October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics